Idogen publishes interim report for 1 January – 30 September 2022
Idogen AB's interim report for January to September 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/
Second quarter (July-September 2022)
• Other operating income amounted to KSEK 0 (7,171)
• Operating loss was KSEK -14,343 (-5,249)
• Loss for the quarter totalled KSEK -14,398 (-5,191)
• Cash flow from operating activities was KSEK -9,879 (-9,029)
• Loss per share before dilution was SEK -0.20 (-0.28). Loss per share after dilution was SEK -0.20 (-0.28)
Period (January-September 2022)
• Other operating income amounted to KSEK 159 (10,580)
• Operating loss was KSEK -36,212 (-25,413)
• Loss for the quarter totalled KSEK -36,286 (-25,326)
• Cash flow from operating activities was KSEK -38,111 (-25,116)
• Loss per share before dilution was SEK -0.58 (-1.39). Loss per share after dilution was SEK -0.58 (-1.39)
Significant events in the third quarter
• Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.
• Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8-program.
• An extraordinary general meeting of shareholders on September 6 elected Joakim Söderström as new
chairman and Niklas Wallet as a new member of the Board of Directors.
• Christina Herder is appointed acting CEO after Anders Karlsson.
Significant events in the period
• Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.
• Idogens presented the company’s tolerogenic cell therapy platform at the 5th Antigen-Specific Immune
Tolerance Summit.
• Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from May 15.
• Idogen’s rights issue raise MSEK 41 after issue costs.
• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study
for IDO 8.
• Idogen’s rights issue raise MSEK 41 after issue costs.
• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.
• Idogen strengthens the organization with key competencies for the clinical development phase.
Significant events after the end of the period
• Idogen's Idogen sharpens focus on its IDO 8 program, pauses the IDO T and IDO programs and lowers operating expenditure.
• Idogen receives after exercise of warrants 280 KSEK before costs.
• First patient enters Idogen’s hemophilia study under the IDO 8 program.
• EU to disburse the remaining of the Horizon 2020 grant.
• Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors.
• The board of Idogen propose a rights issue at up to 38 MSEK net after cost.
• Idogen invites for an extra shareholder meeting 13 December
• No other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Christina Herder, Acting CEO, Idogen AB
Tel: +46 70 374 71 56
E-mail: christina.herder@idogen.com
Certified Adviser:
Vator Securities AB
The information was submitted for publication, through the agency of the contact persons set out above, on November 25, 2022 at 08:03 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.